MILESON GLENNA 4
4 · Athira Pharma, Inc. · Filed Jan 6, 2022
Insider Transaction Report
Form 4
MILESON GLENNA
Chief Financial Officer
Transactions
- Award
Common Stock
2021-11-18$12.51/sh+931$11,647→ 90,755 total - Exercise/Conversion
Common Stock
2022-01-04$1.35/sh+6,305$8,512→ 97,060 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-01-04−6,305→ 0 totalExercise: $1.35Exp: 2028-12-17→ Common Stock (6,305 underlying)
Footnotes (4)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).
- [F2]The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.
- [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.
- [F4]The shares subject to the option fully vested on January 1, 2022.